Dual Immunotherapy in Aggressive Lymphoma (DIAL) study, a randomized phase 2 trial of Varlilumab in combination with Nivolumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
The DIAL study, a randomized phase 2 trial, found that adding the CD27 agonist varlilumab to nivolumab did not improve response rates or safety outcomes compared to nivolumab monotherapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer is a disease of uncontrolled growth, but the body possesses a powerful internal defense system designed to stop it: the immune system. In a healthy state, immune cells patrol the body, recognizing and destroying abnormal cells before they can form tumors. However, some cancers, particularly aggressive forms of blood cancer known as lymphomas, have learned to hide or shut down these immune sentinels. To fight back, scientists have developed drugs called immunotherapies. One major class of these drugs works by removing the "brakes" that cancer cells use to stop immune attacks, effectively waking up the body's own defenses. Another approach involves using antibodies to stimulate specific receptors on immune cells, acting like a gas pedal to encourage them to multiply and attack more vigorously. While these treatments have revolutionized care for many cancers, their success in treating aggressive B-cell lymphoma has been mixed. Patients who have already tried standard chemotherapy and even advanced cell therapies often face a grim outlook, leaving doctors and researchers searching for new ways to combine these immune-boosting tools to save lives.
In the DIAL study, a team of researchers from major medical centers across the United States tested a specific combination strategy for patients with relapsed or refractory aggressive B-cell lymphoma. These are patients whose cancer has returned or failed to respond to at least two previous lines of standard treatment. The researchers focused on two drugs: Nivolumab, which removes the brakes on the immune system, and Varlilumab, which acts as a stimulant for a different part of the immune system called the CD27 receptor. The logic was that using both drugs together might create a powerful synergy, waking up the immune system from multiple angles to overcome the cancer's defenses. The study enrolled 54 adult patients and randomly assigned them to receive either Nivolumab alone or the combination of Nivolumab and Varlilumab. The goal was to see if adding the second drug improved the chances of the cancer shrinking or disappearing compared to using the first drug by itself.
The results of the trial were clear and, unfortunately, did not support the initial hope that the combination would be superior. Out of the 51 patients who received the assigned treatment, only six achieved an objective response, meaning their tumors shrank significantly or disappeared. This overall response rate was just 12 percent. When the researchers broke down the numbers, they found that 16 percent of patients in the group receiving Nivolumab alone responded to the treatment, while only 7.6 percent of those receiving the combination therapy responded. The difference between the two groups was not statistically significant, indicating that adding Varlilumab did not improve the outcome. Furthermore, the few patients who switched from the single-drug group to the combination group after their disease progressed did not respond to the addition of the second drug. The study also looked at patients who had previously received CAR-T cell therapy, a highly advanced treatment where a patient's own immune cells are genetically modified to fight cancer. Even in this subgroup, the response rates remained low, with no meaningful difference between those who received the single drug and those who received the combination.
Beyond the lack of improved effectiveness, the researchers also examined the safety of the combination. They found that the rate of side effects was similar between the two groups. Serious adverse events occurred in about three-quarters of the patients in both arms of the study, and there were no treatment-related deaths. This confirmed that adding Varlilumab did not make the treatment more dangerous, but it also meant that the combination offered no benefit in terms of survival or disease control. The median time patients survived without their disease getting worse was roughly two to three months, and the median overall survival was less than seven months for the control group and under four months for the combination group, with no significant difference between them. The researchers also attempted to analyze tumor tissue and blood samples to find biological clues that might predict who would respond to the treatment. However, these exploratory analyses failed to identify any specific genetic or immune features that could explain why a few patients responded while most did not.
The study concludes that for patients with relapsed or refractory aggressive B-cell lymphoma, adding Varlilumab to Nivolumab does not improve outcomes. The combination was safe but ineffective, offering no advantage over the single drug. This finding suggests that simply stacking two different types of immune-boosting drugs is not enough to overcome the complex ways these aggressive lymphomas evade the immune system. The results reinforce the idea that immune checkpoint inhibitors, whether used alone or in combination, are not a reliable rescue therapy for this specific patient population, especially after they have already failed other advanced treatments like CAR-T cell therapy. While a small number of patients did experience durable responses, the researchers could not determine who those patients were or why they responded, leaving a critical gap in understanding how to select the right candidates for this type of therapy. The study stands as a necessary step in medical research, ruling out a promising-sounding combination and highlighting the urgent need for new strategies and better biomarkers to guide future treatments for these difficult-to-treat cancers.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.